跳至主要内容
临床试验/NCT01894867
NCT01894867Unknown4 期

Magnesium Deficiency in Cirrhotic Patients

Meir Medical Center1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年8月最近更新:
适应症

试验速览

阶段
4 期
入组人数
50
试验地点
1
主要终点
change in minimal hepatic encephalopathy

研究概览

简要总结

Several studies have shown in patients magnesium deficiency with liver cirrhosis.

Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium.

We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

详细描述

Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions.

There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem.

Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis.

There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps).

The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with liver cirrhosis

排除标准

  • pregnant women
  • Patients with acute or chronic renal failure (cr>1.5)
  • Congestive heart failure NYHA 3-4
  • Patient with active cancer
  • Patients with dementia or mental retardation

结局指标

主要结局

change in minimal hepatic encephalopathy

时间窗: 6 weeks

次要结局

  • change in muscle weakness(6 weeks after intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Magnesium in Liver Cirrhosis | 临床试验